[Acebutolol in the therapy of mild and moderate hypertension]

Acebutolol (sectral) is one of the new types of cardioselective beta-blockers which has at the same time also qualities of ISA. The author made a 6-month clinical study comprising 20 patients, focused on the antihypertensive effectiveness and tolerance of the drug. Administration of acebutolol led already after two weeks to a significant effect on the systolic and diastolic blood pressure and during the period of 1-6-month administration the maximal antihypertensive effect was achieved (-29 mm Hg systolic BP, -19 mm Hg diastolic BP). 24-hour monitoring of the BP proved antihypertensive effectiveness of acebutolol regardless whether the drug was administered in two daily doses or only once a day. In the course of the investigation no negative metabolic effects of acebutolol were observed.